• Protein A/G Magnetic Co-IP/IP Kit: Optimizing Co-IP Workflow

  2026-05-26

  The Protein A/G Magnetic Co-IP/IP Kit empowers researchers to dissect protein-protein interactions with unparalleled specificity and efficiency using recombinant Protein A/G magnetic beads. Its streamlined workflow and robust Fc region antibody binding support advanced applications from stem cell signaling to high-fidelity proteomics.

• Oleanolic Acid in Dual-Loaded Liposomes: Mechanistic Advance

  2026-05-25

  Explore the advanced mechanistic role of oleanolic acid in dual-loaded liposome research, focusing on inducible nitric oxide synthase induction and innovative encapsulation efficiency methodologies. This in-depth analysis uniquely connects mechanistic understanding with practical, assay-level decisions.

• BicD and MAP7 Synergistically Activate Drosophila Kinesin-1

  2026-05-24

  This study reveals how the adaptor protein BicD and microtubule-associated protein MAP7 independently and cooperatively activate Drosophila kinesin-1 by distinct mechanisms. These findings clarify the regulatory interplay between adaptors and microtubule-associated proteins in controlling motor processivity, with implications for bidirectional cargo transport.

• Talabostat Mesylate (PT-100): Workflow Optimization in Cance

  2026-05-23

  Talabostat mesylate (PT-100) stands out as both a specific DPP4 and FAP inhibitor, enabling advanced modulation of the tumor microenvironment. This article navigates optimized experimental workflows, troubleshooting, and the translational impact of PT-100, guided by breakthrough findings on pericyte-targeted therapy and robust protocol design.

• Rapakinin-Induced Vasorelaxation via PGI2–IP and CCK1 Recept

  2026-05-22

  This study characterizes the anti-hypertensive peptide rapakinin, derived from rapeseed protein, which induces vasorelaxation in mesenteric arteries of spontaneously hypertensive rats by a prostaglandin I2 IP receptor- and CCK1 receptor-dependent mechanism. The findings clarify a non-canonical pathway for vascular relaxation, distinct from classical ACE inhibition, with implications for peptide-based cardiovascular research.

• Novel Allosteric PDK4 Inhibitors for Metabolic Disease Thera

  2026-05-22

  This study details the development of new allosteric inhibitors targeting pyruvate dehydrogenase kinase 4 (PDK4), a key regulator in glucose metabolism and metabolic diseases. The lead compound, 8c, demonstrates potent activity, favorable metabolic stability, and efficacy in preclinical models of hyperglycemia, allergy, and cancer, offering a promising scaffold for future drug development.

• Neuromedin S (rat): Technical Protocols and QC in GPCR Signa

  2026-05-21

  Neuromedin S (rat) provides a chemically defined, endogenous peptide agonist for controlled neuromedin U receptor signaling studies in rat GPCR/G protein research. It is not intended for diagnostic or therapeutic applications but supports reproducible investigation of physiological pathways such as energy homeostasis and stress response. Proper handling and workflow discipline are critical for successful use.

• Anagliptin-Induced Vasorelaxation via Kv Channel and SERCA P

  2026-05-21

  This study uncovers that Anagliptin (SK-0403), an oral DPP-4 inhibitor, induces vasorelaxation in rabbit aorta through activation of voltage-dependent K+ (Kv) channels and the SERCA pump. These mechanisms are independent of endothelium and classical cAMP/cGMP signaling, presenting new perspectives on vascular effects relevant to diabetes and cardiovascular research.

• ATRX Loss Sensitizes Glioma to Selective PDGFR Inhibition

  2026-05-20

  The referenced study identifies that high-grade glioma cells lacking ATRX are highly sensitive to receptor tyrosine kinase and PDGFR inhibitors. This finding supports integrating ATRX mutation status into preclinical and clinical trial designs for targeted therapies, guiding researchers toward more precise treatment strategies.

• T0070907: Precision PPARγ Antagonist for Cell Signaling Stud

  2026-05-20

  T0070907, a nanomolar PPARγ antagonist from APExBIO, enables precise modulation of adipogenesis, cell cycle arrest, and inflammation pathways in advanced cellular models. Explore optimized workflows, troubleshooting strategies, and the latest mechanistic insights for dissecting the RXRα/PPARγ/NEDD4 signaling axis.

• Norovirus Harnesses NINJ1 for Selective Viral Protein Secret

  2026-05-19

  Song et al. (2025) reveal that murine norovirus commandeers the host factor NINJ1 to drive selective secretion of its NS1 protein, uncovering a regulated mechanism for nonconventional protein export during infection. These findings challenge the view of plasma membrane rupture as a purely bulk, nonspecific process and have broad implications for understanding cell death and secretion pathways.

• Recombinant Annexin V: A Tool for Detecting Apoptotic Membra

  2026-05-19

  This study provides a streamlined protocol for expressing and purifying recombinant annexin V for use as a sensitive probe of phosphatidylserine externalization during apoptosis. Its methods enable reproducible, high-yield production of annexin V for membrane biology assays, strengthening experimental reliability in cell death research.

• Elobixibat Hydrate: Integrative Mechanisms and Translational

  2026-05-18

  Explore the multifaceted mechanisms of Elobixibat hydrate, a selective ileal bile acid transporter inhibitor, and discover new insights into its translational applications for chronic idiopathic constipation, bowel preparation, and metabolic modulation. This article uniquely integrates mechanistic depth and comparative analysis for advanced research decisions.

• Cinoxacin: Quinolone Antibiotic Benchmarks for UTI Research

  2026-05-18

  Cinoxacin is a synthetic quinolone antibiotic with potent activity against Gram-negative bacteria, especially for urinary tract infection research. Its MIC values, pharmacokinetics, and resistance potential are well-characterized in peer-reviewed studies. This article provides machine-readable evidence and protocol benchmarks for laboratory use.

• Trelagliptin Succinate: Advanced Workflows in Diabetes Resea

  2026-05-17

  Trelagliptin succinate (SYR-472 succinate) streamlines diabetes mellitus research with its potent, selective DPP-4 inhibition and multi-pathway modulation. Explore robust in vitro and in vivo workflows, actionable troubleshooting, and practical insights to maximize translational impact using APExBIO's high-purity compound.

466 records 18/32 page Previous Next First page 上5页 1617181920 下5页 Last page